102 results about "Interleukin receptor" patented technology

The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example IL-15 (SEQ ID NO: 5, 6), IL-2 (SEQ ID NO: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example IL-15Ra (SEQ ID NO: 7, 8), IL-2Ra (SEQ ID NO: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, SCID, AIDS, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or Lupus. The therapeutic complex of the invention surprisingly demonstrates increased half-life, and efficacy in vivo.

The present invention provides novel nucleic acids, the novel polypeptide sequences encoded by these nucleic acids and uses thereof. These novel polynucleotide and polypeptide sequences were determined to be a novel Interleukin-1 Receptor Antagonist.

Methods and compositions for inhibiting interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating, ameliorating or preventing autoimmune or inflammatory disorders, including, e.g., inflammatory bowel disease (IBD), rheumatoid arthritis (RA), transplant/graft rejection, psoriasis, asthma, fibrosis, and systemic lupus erythematosus (SLE).

Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating adipose tissue and/or adipocytes with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.

This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin receptor gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of interleukin and/or interleukin receptor genes such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, and IL-27 genes and IL-IR, IL-2R, IL-3R, IL-4R, IL-5R, IL-6R, IL-7R, IL-8R, IL-9R, IL-10R, IL-11R, IL-12R, IL-13R, IL-14R, IL-15R, IL-16R, IL-17R, IL-18R, IL-19R, IL-20R, IL-21R, IL-22R, IL-23R, IL-24R, IL-25R, IL-26R, and IL-27R genes.

A preventive and/or therapeutic agent for systemic lupus erythematosus comprising an anti-interleukin-6 (IL-6) receptor antibody as an active ingredient.

Methods and treatments for osteolysis employing interleukin-1 receptor antagonist (IL-1ra). Activating production of interleukin-1 receptor antagonist includes incubating adipose tissue, adipocytes, whole blood, platelet rich plasma, and/or isolated white blood cells with polyacrylamide beads to produce a solution rich in interleukin-1 receptor antagonist. Activating the production of interleukin-1 receptor antagonist includes using an implantable device loaded with adipose tissue, adipocytes, whole blood, platelet rich plasma, and/or isolated white blood cells. Methods for treating osteolysis at the site of an artificial joint in a patient include administering and/or inserting the solution rich in interleukin-1 receptor antagonist and/or the implantable device, respectively.

The present invention relates generally to antibodies that bind to the Interleukin-13 receptor α1 chain (IL-13Rα1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13Rα1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13Rα1/ligand interaction is also provided.

The present invention relates to use of interleukin-13 as a cardiovascular disease marker. The therapeutic composition and diagnostic composition of the invention for cardiovascular diseases are characterized by comprising an antibody to an interleukin-13 receptor and/or an antibody to interleukin-13.

The invention discloses a method for preparing codon-optimized human interleukin-17 receptor (HIL-17RA) and human serum albumin (HSA) fusion proteins and a product, and discloses construction and preparation of fusion proteins and application of the fusion proteins in the aspect of disease treatment. The method and the product have the advantages that expression of the modified (codon-optimized) fusion proteins in prokaryotic cells can be obviously improved; polypeptide fragments from the HIL-17RA and the human serum albumin (HSA) are fused with one another to obtain the fusion proteins, the problem of easy degradation of natural IL-17RA proteins can be solved by the optimized HIL-17RA-HSA fusion proteins, and the optimized HIL-17RA-HSA fusion proteins are high in biological activity and expression quantity; the method and the product have important actual significance and broad application prospects in the field of medicine and biological pharmacy.

The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of interleukin-1 receptor antagonist (IL-1RA) to result in IL-1RA proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.

The invention relates to the technical field of molecular biology, and in particular relates to a recombinant protein, a protein compound containing the recombinant protein and application. The recombinant protein disclosed by the invention is composed of a human interleukin 1 receptor antagonist protein and a protein containing a VPGKG repetitive unit, can be used for adjuvant therapy of rheumatoid arthritis, acute gouty arthritis and other rheumatic immune diseases, hereditary diseases and tumours with increased interleukin 1 (interleukin, IL-1), and has a remarkable curative effect.

The invention provides a preparation method and application of a transgenic mouse with severe immunodeficiency. The method comprises the step of knocking out a gene for encoding a gamma chain of an interleukin-2 receptor in a mouse chromosome through a CRISPR/CAS9 technology, exons 1 and 2 of a gene of a gamma chain of an interleukin-2 receptor are selected as knockout sites, and Cas9 messenger RNA and guide RNA are jointly injected into fertilized eggs of a mouse through microinjection. The mouse with severe immunodeficiency cannot generate T, B and NK immune cells, so that the greatest convenient condition is created for transplantation of human hematopoietic stem cells.

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (IL-36R). The invention provides an IL-36R-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-36R-binding agent to treat a disorder or disease that is responsive to IL-36R inhibition, such as cancer, an infectious disease, or an autoimmune disease.